Weight Management

A post hoc analysis of ATTAIN-1 and ATTAIN-2 presented at ADA 2026 found orforglipron (Foundayo) significantly reduced body weight and waist circumference in women regardless of menopausal stage.

The misinformation is rampant, the adverse effect expectations are wildly off, and the patient psychology is complex.

Patients deserve more than marketing. They deserve context.

The policy direction is clear, but the regulatory mechanics are still working their way through the system.

As retatrutide moves toward FDA submission, Jennifer Goldman, PharmD, breaks down the TRIUMPH-1 data—and what they mean for patient selection, dose escalation counseling, and positioning within the antiobesity pipeline.

Emerging evidence suggests that some individuals develop nutritional deficiencies during treatment, whereas others experience biologically driven GLP-1 resistance.

Clinical pharmacists may play an increasingly important role in longitudinal metabolic care, medication optimization, patient education, and multidisciplinary peptide management.

GLP-1 receptor agonists may reduce asthma flare-ups in nondiabetic adults with obesity, hinting at anti-inflammatory benefits.

Eli Lilly's investigational triple hormone receptor agonist achieved average weight loss of up to 70.3 lb over 80 weeks.

New once-daily oral GLP‑1 agonist cuts hemoglobin A1c and drives 5% to 10% weight loss—with no fasting rules—expanding options for obesity and diabetes care.

OTC GLP-1 boosters are marketed for weight loss, but pharmacists should help patients distinguish evidence-based care from supplement claims.

Data from the STEP UP trial support semaglutide 7.2 mg as a well-tolerated option for patients who need greater weight reduction.

Metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely underdiagnosed and asymptomatic, creating major opportunities for pharmacists to drive early identification, lifestyle intervention, and metabolic risk management.

A recent report of liver failure in a patient receiving orforglipron has renewed attention on the long-term safety monitoring of GLP-1 receptor agonists.

A new oral GLP-1 therapy could reshape obesity treatment by improving access, convenience, and patient uptake compared with injectable options.

The agency's proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List signals that large-scale compounding of these agents has no regulatory future, and carries immediate implications for pharmacy practice.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1.3 billion people globally, driven by metabolic disease trends, highlighting urgent needs for earlier detection, prevention, and pharmacist-led intervention.

A large multicohort analysis highlights obesity as a modifiable risk factor for severe infectious outcomes, reinforcing the pharmacist’s role in prevention, vaccination, and chronic disease management.

Real-world data show pharmacist-driven obesity care models may offer greater improvements in hemoglobin A1C and lipid parameters while supporting multidisciplinary, patient-centered care.

Direct-to-consumer offerings were a shot across the bow. Direct-to-employer offerings are a torpedo to the midship of the PBM business model.

New analysis suggests oral semaglutide may offer improved efficacy and tolerability compared with orforglipron, informing treatment selection in an increasingly competitive oral GLP-1 landscape.

The approval is supported by clinical data from the ATTAIN-1 and ATTAIN-2 trials.

There was limited evidence supporting additional clinical benefits.

From a pipeline exploding with oral and injectable options to emerging evidence in liver disease, substance use disorder, and kidney disease, Emily Eddy, PharmD, laid out the full scope of incretin therapy's expanding reach at APhA2026.

Experts discuss immunotherapy overlap, nutrition challenges, and clinical judgment with GLP-1 RA use.